Table 1: Baseline clinical characteristics of the study cohort.

Characteristic

Total n = 106

Age, years

 

Mean (SD)

66.2 (10.0)

Median (range)

67 (31–88)

Gender, n (%)

 

Male

57 (53.8)

Female

49 (46.2)

Stage at enrollment, n (%)

 

IIIA

10 (9.4)

IIIB

8 (7.6)

IV

88 (83)

Histology, n (%)

 

Adenocarcinoma

84 (79.2)

Carcinoma NOS

2 (1.9)

NSCLC

11 (10.4)

SCLC

3 (2.8)

SQ

4 (3.8)

No histology

2 (1.9)

Status of disease, n (%)

 

Initially diagnosed

89 (84.0)

Recurrence

8 (7.5)

On-treatment

9 (8.5)

ECOG performance status, n (%)

0

29 (27.3)

1

44 (41.5)

2

15 (14.2)

3

3 (2.8)

Unknown

15 (14.2)

EGFR gene, n (%)

 

Positive

18 (17.0)

Negative

62 (58.5)

Unknown

26 (24.5)

Smoking, n (%)

 

Never

21 (19.8)

Former

17 (16.0)

Current

35 (33.0)

Unknown

33 (31.2)

SD: Standard Deviation;
NOS: Not Otherwise Specified;
NSCLC: Non-Small Cell Lung Cancer;
SCLS: Small Cell Lung Cancer;
SQ: Squamous Cell Carcinoma;
ECOG: Eastern Cooperative Oncology Group;
EGFR : Epidermal Growth Factor Receptor